SG11201907715YA - Antigen receptors and uses thereof - Google Patents
Antigen receptors and uses thereofInfo
- Publication number
- SG11201907715YA SG11201907715YA SG11201907715YA SG11201907715YA SG11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA SG 11201907715Y A SG11201907715Y A SG 11201907715YA
- Authority
- SG
- Singapore
- Prior art keywords
- mainz
- der
- international
- antigen receptors
- pct
- Prior art date
Links
- 102000006306 Antigen Receptors Human genes 0.000 title abstract 5
- 108010083359 Antigen Receptors Proteins 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/30—Mixture of cells
-
- A61K39/4611—
-
- A61K39/4631—
-
- A61K39/4632—
-
- A61K39/464402—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT omit VIII °nolo O II oimIE (10) International Publication Number WO 2018/167151 Al (51) International Patent Classification: CO7K 14/705 (2006.01) A61K 38/17 (2006.01) CO7K 14/725 (2006.01) (21) International Application Number: PCT/EP2018/056399 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: PCT/EP2017/056086 14 March 2018 (14.03.2018) English English Published: — with international search report (Art. 21(3)) 15 March 2017 (15.03.2017) EP (71) Applicants: BIONTECH CELL & GENE THERAPIES GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). TRON — TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JO- HANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE). UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ [DE/DE]; Langenbeckstrasse 1, 55131 Mainz (DE). (72) Inventors: VOSS, Ralf Holger; Lotharstrasse 32, 55218 Ingelheim (DE). SAHIN, Ugur; c/o BioNTech AG, An der Goldgrube 12, 55131 Mainz (DE). SIMON, Petra; c/o BioNTech AG, An der Goldgrube 12, 55131 Mainz (DE). BIRTEL, Matthias; Boppstrasse 1, 55118 Mainz (DE). CASPAR, Janina; Genheimerstrasse 16, 55425 Wal- dalgesheim (DE). (74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwalte PartG mbB, Hansastr. 32, 80686 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTIGEN RECEPTORS AND USES THEREOF (57) : The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2017/056086 WO2018166589A1 (en) | 2017-03-15 | 2017-03-15 | Antigen receptors and uses thereof |
PCT/EP2018/056399 WO2018167151A1 (en) | 2017-03-15 | 2018-03-14 | Antigen receptors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907715YA true SG11201907715YA (en) | 2019-09-27 |
Family
ID=58360981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907715YA SG11201907715YA (en) | 2017-03-15 | 2018-03-14 | Antigen receptors and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US11702631B2 (en) |
EP (1) | EP3596113B1 (en) |
JP (1) | JP7073417B2 (en) |
KR (1) | KR102396925B1 (en) |
CN (1) | CN110621693B (en) |
AU (1) | AU2018234068B2 (en) |
BR (1) | BR112019018705A2 (en) |
CA (1) | CA3054253A1 (en) |
ES (1) | ES2886189T3 (en) |
IL (1) | IL269213B2 (en) |
MX (1) | MX2019010941A (en) |
NZ (1) | NZ756383A (en) |
SG (1) | SG11201907715YA (en) |
WO (2) | WO2018166589A1 (en) |
ZA (1) | ZA201905441B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017059900A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
CN118139897A (en) * | 2021-11-05 | 2024-06-04 | 清华大学 | Synthetic T cell receptor antigen receptor specifically combined with mesothelin and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409577A (en) | 1966-07-06 | 1968-11-05 | Owens Corning Fiberglass Corp | Method of detackifying tacky resins |
US6534633B1 (en) * | 1998-10-21 | 2003-03-18 | Altor Bioscience Corporation | Polyspecific binding molecules and uses thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2008253720B2 (en) * | 2007-05-11 | 2014-01-16 | Altor Bioscience Corporation | Fusion molecules and IL-15 variants |
EP2502934B1 (en) * | 2011-03-24 | 2018-01-17 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds |
WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
SG10201914069SA (en) * | 2015-05-18 | 2020-03-30 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
WO2017059900A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
-
2017
- 2017-03-15 WO PCT/EP2017/056086 patent/WO2018166589A1/en active Application Filing
-
2018
- 2018-03-14 IL IL269213A patent/IL269213B2/en unknown
- 2018-03-14 KR KR1020197030007A patent/KR102396925B1/en active IP Right Grant
- 2018-03-14 MX MX2019010941A patent/MX2019010941A/en unknown
- 2018-03-14 JP JP2019571780A patent/JP7073417B2/en active Active
- 2018-03-14 CA CA3054253A patent/CA3054253A1/en active Pending
- 2018-03-14 BR BR112019018705A patent/BR112019018705A2/en unknown
- 2018-03-14 CN CN201880031971.9A patent/CN110621693B/en active Active
- 2018-03-14 WO PCT/EP2018/056399 patent/WO2018167151A1/en active Application Filing
- 2018-03-14 US US16/493,618 patent/US11702631B2/en active Active
- 2018-03-14 EP EP18710059.9A patent/EP3596113B1/en active Active
- 2018-03-14 SG SG11201907715YA patent/SG11201907715YA/en unknown
- 2018-03-14 AU AU2018234068A patent/AU2018234068B2/en active Active
- 2018-03-14 NZ NZ756383A patent/NZ756383A/en unknown
- 2018-03-14 ES ES18710059T patent/ES2886189T3/en active Active
-
2019
- 2019-08-16 ZA ZA2019/05441A patent/ZA201905441B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018234068A1 (en) | 2019-09-05 |
EP3596113B1 (en) | 2021-08-04 |
RU2019125594A (en) | 2021-04-15 |
ES2886189T3 (en) | 2021-12-16 |
NZ756383A (en) | 2023-03-31 |
CA3054253A1 (en) | 2018-09-20 |
RU2019125594A3 (en) | 2021-06-09 |
JP7073417B2 (en) | 2022-05-23 |
IL269213B2 (en) | 2023-11-01 |
JP2020509783A (en) | 2020-04-02 |
US20200063101A1 (en) | 2020-02-27 |
US11702631B2 (en) | 2023-07-18 |
AU2018234068B2 (en) | 2021-10-21 |
IL269213A (en) | 2019-11-28 |
WO2018166589A1 (en) | 2018-09-20 |
KR20190128683A (en) | 2019-11-18 |
MX2019010941A (en) | 2019-12-19 |
ZA201905441B (en) | 2020-11-25 |
IL269213B1 (en) | 2023-07-01 |
KR102396925B1 (en) | 2022-05-13 |
WO2018167151A1 (en) | 2018-09-20 |
CN110621693B (en) | 2024-01-12 |
EP3596113A1 (en) | 2020-01-22 |
CN110621693A (en) | 2019-12-27 |
BR112019018705A2 (en) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201406963RA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG11201406977TA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201804162WA (en) | Compositions comprising bacterial strains | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201805579SA (en) | Recombinant igg fc multimers | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201906961UA (en) | Polypeptide variants and uses thereof | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
SG11201803642WA (en) | Bacteria-based protein delivery | |
SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel |